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Autism spectrum disorders (ASD) are a group of developmental disorders characterized by  severe abnormalities  in  communications, social awareness  and  skills,  along with  presence  of  restrictive  activities [1]. In addition, there is evidence of involvement of various ge-neric and environmental factors.  There is a growing awareness of the condition, diagnostic substitution and emerging research explains the rise in incidence of ASD. Despite existence of best practice guidelines for ASD diagnosis, which are recognised internationally [2], there is inconsistency in the reporting by the professionals [3]. However, experts believe that the actual rate of incidence could be higher, and 
only limited number of cases are identified by available definitive diagnosis [4,5]. Further, heterogeneity of ASD poses significant chal-
lenge in identifying specific biomarkers [1].In ASD, medications often target problems such as irritability, aggression, self-injury, hyperactivity, and inattention, rather than the 
core symptoms of the disorder [6,7].  Core symptoms can be defined as withdrawal from the social domain and typical restricted/repeti-tive symptoms in the behavior domain [6].  Though, several studies on treatment of ASD have been evaluated, there are considerable 
variables in the results reported leading to the lack of consistent findings [8]. These variables are seen in certain aspects of research 
methodology used (such as lack of control, heterogeneous samples, and imprecise measurement), type of clinical practice, and differences 
in social settings of the studies [9]. Moreover, the efficacy and tolerability of these medications in children with ASD is less favorable than data available in typically developing children with similar symptoms [7,8]. 
It is acknowledged that there are studies which describe the research in different aspects of therapeutic findings. However, lack of a 
valid and reliable clinical trial can be a big hindrance to translation of the research for autism. Medications which are not effective should 
probably be abandoned as potential treatments and those that are effective possibly should be considered for more research [6]. Esca-lating research in pharmacological interventions and understanding of pathogenic pathways can help in development of new and novel medications for treatment of core symptoms in ASD.
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